Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An 8-week, randomized, double-blind, placebo-controlled, multi-centre study of [S,S]-reboxetine administered once daily in patients with fibromyalgia

Next Previous
X
Search
Trial Profile

An 8-week, randomized, double-blind, placebo-controlled, multi-centre study of [S,S]-reboxetine administered once daily in patients with fibromyalgia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Esreboxetine (Primary)
  • Indications Fibromyalgia; Musculoskeletal pain
  • Focus Registrational; Therapeutic Use
  • Sponsors Pfizer

    • Most Recent Events

    • 05 Aug 2024 According to Axsome Therapeutics media release, NDA submission for AXS-14 in fibromyalgia expected 3Q 2024.
    • 06 May 2024 According to an Axsome Therapeutics media release, Pre-submission activities for the Companys NDA for AXS-14 for the management of fibromyalgia are nearing completion. NDA submission for AXS-14 in fibromyalgia expected in 2Q 2024.
    • 07 Aug 2023 According to Axsome Therapeutics media release, company now expects to submit the NDA in the fourth quarter of 2023 or the first quarter of 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top